Transcode Therapeutics Inc (RNAZ)
$2.10
$-0.08
(-3.67%)
As on 31-Aug-2026 16:23EDT
Market cap
$2 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-47
-
Face value
--
-
Shares outstanding
1,058,481
6 Years Aggregate
CFO
$-40.40 Mln
EBITDA
$-43.38 Mln
Net Profit
$-64.12 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Transcode Therapeutics Inc (RNAZ)
| -69.3 | -60.0 | -59.1 | -78.4 | -96.7 | -93.7 | -- |
|
BSE Sensex
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Transcode Therapeutics Inc (RNAZ)
| -92.8 | -98.4 | -98.8 | -73.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Transcode Therapeutics Inc (RNAZ)
|
2.1 | 2.4 | 0.0 | -42.8 | -- | -29.5 | -- | 2.8 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 147.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Transcode Therapeutics Inc (RNAZ)
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of... patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts. Read more
-
Interim CEO, CFO, President, VP of Administration & Director
Mr. Thomas A. Fitzgerald M.B.A.
-
Interim CEO, CFO, President, VP of Administration & Director
Mr. Thomas A. Fitzgerald M.B.A.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Transcode Therapeutics Inc (RNAZ)
What is the current share price of Transcode Therapeutics Inc (RNAZ) Today?
The share price of Transcode Therapeutics Inc (RNAZ) is $2.10 (NASDAQ) as of 31-Aug-2026 16:23 EDT. Transcode Therapeutics Inc (RNAZ) has given a return of -96.66% in the last 3 years.
What is the current PB & PE ratio of Transcode Therapeutics Inc (RNAZ)?
Since, TTM earnings of Transcode Therapeutics Inc (RNAZ) is negative, P/E ratio is not available.
The P/B ratio of Transcode Therapeutics Inc (RNAZ) is 2.83 times as on 28-Aug-2026, a 45 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.18 |
0.61 |
2024 |
-0.07 |
-0.59 |
2023 |
0.00 |
0.00 |
2022 |
0.00 |
0.01 |
2021 |
-0.01 |
0.00 |
What is the 52 Week High and Low of Transcode Therapeutics Inc (RNAZ)?
The 52-week high and low of Transcode Therapeutics Inc (RNAZ) are Rs 20.99 and Rs 1.83 as of 01-Sep-2026.
What is the market cap of Transcode Therapeutics Inc (RNAZ)?
Transcode Therapeutics Inc (RNAZ) has a market capitalisation of $ 2 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Transcode Therapeutics Inc (RNAZ)?
Before investing in Transcode Therapeutics Inc (RNAZ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.